Previous 10 | Next 10 |
2024-02-20 09:00:00 ET Summary Moderna has surged 40% from its November 2023 lows through last week's close. Buyers returned to buy the "bad news" from its Q3 earnings reset. The recent worse-than-anticipated data release for its RSV vaccine contributed to a recent pullback in MRN...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-02-16 15:00:59 ET More on the markets SPY Pullback Triggers Sell Signal (Technical Analysis) SPY: Up 14 Weeks Out Of Last 15 - I'm Out SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In Investors retract capital from the fund market for ...
2024-02-16 12:58:16 ET Summary Moderna has become a household name due to its COVID vaccine during the pandemic. However, cracks are beginning to show for mRNA vaccines when compared with traditional vaccines. As such, I believe Moderna faces significant risks and competition ...
2024-02-15 02:45:38 ET Summary GSK plc is a multinational “big pharma” and long-time leader in the vaccine, HIV, and respiratory disease areas. Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no sign of slowing down. GSK’s f...
2024-02-14 11:43:00 ET More on BioNTech, Moderna, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Pfizer: The 6.3% Yield Is A Appealing Federal judge dismisses PhRMA challenge to Medicare price negotiations ...
2024-02-13 09:30:44 ET More on GSK GSK plc (GSK) Q4 2023 Earnings Call Transcript GSK plc 2023 Q4 - Results - Earnings Call Presentation GSK: Robust Earnings Report Expected, 2024 Outlook Is Key Moderna RSV vaccine lags rival shots in long-term efficacy: TD C...
2024-02-13 08:25:14 ET Summary Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ability to execute business development activities a...
2024-02-13 07:00:00 ET There's arguably no better time to buy a stock than when it's been beaten down. Doing so provides a reasonable entry point for investors willing to hold the stock for a while, which can translate to outsized returns in time. Of course, not every stock lagging the mark...
2024-02-12 07:18:25 ET More on Pfizer Pfizer Is A Great Investment Over The Next Decade; Buy Pfizer: The 6.3% Yield Is A Appealing Pfizer: Simply Too Cheap To Ignore Moderna RSV vaccine lags rival shots in long-term efficacy: TD Cowen Pfizer, Arvinas'...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...